GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » YoY EPS Growth

PMN (ProMIS Neurosciences) YoY EPS Growth : 51.85% (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. ProMIS Neurosciences's YoY EPS Growth for the quarter that ended in Jun. 2024 was 51.85%.

ProMIS Neurosciences's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $-0.13.

ProMIS Neurosciences YoY EPS Growth Historical Data

The historical data trend for ProMIS Neurosciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences YoY EPS Growth Chart

ProMIS Neurosciences Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.79 31.71 -79.60 -42.60 55.60

ProMIS Neurosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.95 77.11 79.12 67.24 51.85

ProMIS Neurosciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

ProMIS Neurosciences's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.07--2.41)/ | -2.41 |
=55.60 %

ProMIS Neurosciences's YoY EPS Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EPS Growth (Q: Jun. 2024 )
=(Earnings per Share (Diluted) (Q: Jun. 2024 )-Earnings per Share (Diluted) (Q: Jun. 2023 )) / | Earnings per Share (Diluted) (Q: Jun. 2023 )) |
=(-0.13--0.27)/ | -0.27 |
=51.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » YoY EPS Growth
Comparable Companies
EYEN NXTC TARA UNCY KZR AEON LTRN AKTX FGEN PVCT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 ALNY XBRU:UCB XBRU:ARGX XKRX:068270 BNTX
Traded in Other Exchanges
23J0:Germany
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
Website
https://www.promisneurosciences.com
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Executives
Madge K. Shafmaster director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel officer: Chief Medical Officer C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar 10 percent owner 33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel director, officer: Chief Executive Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury officer: Principal Accounting Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant officer: Chief Operating Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman director, officer: Chief Scientific Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan officer: Chief Development Officer PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams director, officer: Chairman and CEO C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory director 830 WINTER STREET, WALTHAM MA 02451
Neil K Warma director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman director 4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2